{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Factor+VIIa&page=2",
    "query": {
      "intervention": "Recombinant Factor VIIa",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Factor+VIIa&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T13:01:20.120Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00810888",
      "title": "The Spot Sign for Predicting and Treating ICH Growth Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "recombinant activated factor VII",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 92,
      "start_date": "2010-11",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2018-03-16",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • San Diego, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00810888"
    },
    {
      "nct_id": "NCT02418793",
      "title": "A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "MOD-5014",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2015-05",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02418793"
    },
    {
      "nct_id": "NCT00710619",
      "title": "Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "Feiba VH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 52,
      "start_date": "2008-06",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-17",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 1,
      "location_summary": "Plainsboro, New Jersey",
      "locations": [
        {
          "city": "Plainsboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00710619"
    },
    {
      "nct_id": "NCT02548143",
      "title": "LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Coagulation Factor VIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "6 Months to 75 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2016-08-25",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548143"
    },
    {
      "nct_id": "NCT01476423",
      "title": "Observational Registry of the Treatment of Glanzmann's Thrombasthenia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Glanzmann's Disease"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 218,
      "start_date": "2004-01",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01476423"
    },
    {
      "nct_id": "NCT01561391",
      "title": "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "factor IX",
          "type": "OTHER"
        },
        {
          "name": "factor VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561391"
    },
    {
      "nct_id": "NCT01564563",
      "title": "Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Bleeding During/Following Surgery"
      ],
      "interventions": [
        {
          "name": "standard therapy",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2002-06-28",
      "completion_date": "2003-10-27",
      "has_results": false,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01564563"
    },
    {
      "nct_id": "NCT01439971",
      "title": "Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "PF-05280602",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catalyst Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "MALE",
        "summary": "18 Years to 64 Years · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2011-12",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 9,
      "location_summary": "San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439971"
    },
    {
      "nct_id": "NCT04023019",
      "title": "Treatment of Hemophilia A Patients With FVIII Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Octanate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wilate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emicizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant factor VIIa (rFVIIa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated prothrombin complex concentrate (aPCC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-03-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04023019"
    },
    {
      "nct_id": "NCT07227246",
      "title": "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biological/Vaccine: Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Broderick, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 350,
      "start_date": "2025-05-06",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-24T13:01:20.120Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227246"
    }
  ]
}